Live Biotherapeutics Drug Discovery Services for Autoimmune Disease
Next-generation probiotics (NGPs) have been investigated to determine potential beneficial effects in autoimmune disease. As an industry leader in the development of NGPs, Creative Biolabs has established an advanced technology platform to provide global researchers with high-quality NGPs development services and promote the exploration of novel therapeutic strategies for autoimmune disease.
Introduction of Autoimmune Disease
The diverse immune system developed to fulfill the primary function of protecting hosts from infectious agents. There are, however, two major areas in which this pleiotropic immune system leads to pathology: first, immune deficiency syndromes in which there is an inability of one or more components of the immune system to respond in a protective fashion to a pathogen, and secondly autoimmune diseases. The failure to distinguish self from nonself has often termed a breach of tolerance and is the basis for autoimmune disease. Because of the ability of probiotics to impact the proliferation and life of pathogenic- and nonpathogenic microorganisms, including those composing intestinal microbiota, along with the impact of probiotics over the immune system, it is feasible to investigate their influence on health and disease.
Fig.1 Schematic representation of the intestinal dysbiosis in organ-specific autoimmune diseases in humans. (de Oliveira, 2017)
NGPs Treatment for Autoimmune Disease
Evidence from animal models has implied the direct involvement of gut microbiota in disease development, and some intestinal microbiota is associated with autoimmune diseases. Probiotics have been investigated to determine potential beneficial effects in the prevention and treatment of autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and childhood allergic asthma. Studies suggest that probiotics influence systemic immune responses, ensure the homeostasis of the healthy microbiota in the intestinal mucosa, and could, therefore, be used as adjuvant therapy to treat immune-mediated diseases. Probiotics can be beneficial to different patients by stimulating the immune response or inhibiting the immune response.
SLE is an autoimmune and heterogeneous disease characterized by damage to the skin, kidneys, lungs, joints, heart, and brain. SLE may involve genetic and environmental factors, such as viral infections, defective apoptosis, and solar exposure to ultraviolet-B waves. Regarding the immune response, it is known that autoantibodies bind mainly with nuclear, and cytoplasmic antigens. Moreover, increasing evidence has emerged that the role of intestinal dysbiosis in SLE development. Both experimental and clinical trials have revealed that selective strains of probiotics (B. bifidum, Ruminococcus obeum, Blautia coccoides, and L. casei strain Shirota) can reduce inflammation and restore tolerance in SLE animal models.
RA is a systemic autoimmune disorder characterized by chronic inflammation of multiple joints, bone erosion, and cartilage destruction. Moreover, RA can affect internal organs such as the lungs, heart, and kidneys. Among environmental factors, dysbiosis has been identified as a possible trigger factor for autoimmunity and RA development. Increasing evidence suggests an association between intestinal dysbiosis and rheumatic diseases and their role in disease progression and the inflammatory microenvironment. Future studies should demonstrate the role of gut inflammation as a trigger for the development of autoimmunity and RA. The determination of an intestinal dysbiotic signature will provide us with the means to develop therapeutic tools for the adjuvant treatment of immune-mediated diseases.
Modern-day society, with increased standards of hygiene, has changed the gut flora of infants, potentially impacting the risk of developing immune-mediated diseases including childhood allergic disease and asthma. Microbial diversity is intrinsic to healthy immune maturation and function. The administration of probiotics may increase human milk TGF-β concentration depending on the probiotic strain. Inverse effects have been seen with Lactobacillus reuteri, and because concentrations of human milk TGF-β may be critical in determining immune function.
NGPs Development Services at Creative Biolabs:
Focusing on the NGPs treatment for years, Creative Biolabs has facilitated researchers all over the world with NGPs development services. Our advanced technology platform and Ph.D. level experts specialized in probiotics are the guarantee of quality service. Our services at Creative Biolabs include but not limited to:
-
Microbial identification services including nucleic acid analytics, protein and amino acid analytics, physical /organoleptic measurement, and whole metagenomic profiling;
-
Biological safety test including CFU count of active microorganisms, identification of cytotoxicity in vitro, skin irritation and sensitization in vitro test, as well as bacteriophage detection;
-
Antibiotic susceptibility/resistance test for NGPs;
-
Host-microbe interaction tests to optimize NGPs therapeutic efficiency;
-
Stress response profiling for NGPs;
-
Fermentation and subsequent downstream purification.
NGPs treatment has shown its potential in the exploration of autoimmune disease therapy. With extensive industry experience and scientists specialized in probiotics, Creative Biolabs provides high-quality NGPs development services to facilitate global researchers in novel approaches to autoimmune disease therapy.
If you are interested in our services, please feel free to contact us.
Reference
-
de Oliveira, G. L. V.; et al. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology. 2017, 152(1): 1-12.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
